{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T11:41:36Z","timestamp":1764502896203,"version":"3.46.0"},"reference-count":40,"publisher":"Practical Medicine Publishing House","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Oncohematology"],"abstract":"<jats:p>Aim.\u00a0To evaluate the efficacy of maintenance therapy in multiple myeloma (MM) patients after autologous hematopoietic stem cell transplantation (auto-HSCT) based on the results of MRI of bone marrow.\r\nMaterials &amp; Methods.\u00a0The study included 32 MM patients aged 36 to 66 years (median 57 years) with complete remission after a single auto-HSCT. MRI of spine and pelvic bones was performed to identify the nature of bone marrow lesions and to determine the volume of tumor tissue on the day 100 after auto-HSCT. As maintenance therapy after auto-HSCT 14 patients received daily 15 mg lenalidomide in the period from day 1 to day 21 of the 28-day treatment course within 1 year. Monitoring of 18 patients was conducted without maintenance therapy. Statistical analysis included the assessment of progression-free survival (PFS) and relapse risk relationship to clinical and laboratory parameters.\r\nResults.\u00a0Twenty patients had a positive MRI (tumor volume\u00a0&gt;\u00a01\u00a0cm3). Zero variation of MR signal in bone marrow and detection of a\u00a0&lt;\u00a01 cm3\u00a0tumor were regarded as a negative MRI, which was the case in 12 patients. After reaching the negative MRI the best rates of 2-year PFS were registered: 100\u00a0% with maintenance therapy and 84\u00a0% without maintenance therapy. In patients with tumor load on MR scans the 2-year PFS significantly (p\u00a0=\u00a00.03) varied and accounted for 80\u00a0% in patients who received maintenance therapy\u00a0vs. 33\u00a0% in patients without maintenance therapy. Administration of maintenance therapy after detecting residual tumor on MR scans on day 100 after auto-HSCT has a positive effect on PFS rates. Multivariate analysis confirmed the residual tumor on MR scans of bone marrow to be the most important parameter PFS depends on.\r\nConclusion.\u00a0A negative MRI after auto-HSCT is a favourable prognostic factor determining a long-lasting (&gt;\u00a02 years) MM free period, despite the lack of maintenance therapy.<\/jats:p>","DOI":"10.21320\/2500-2139-2018-11-4-360-367","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T10:20:27Z","timestamp":1539080427000},"page":"360-367","source":"Crossref","is-referenced-by-count":0,"title":["Magnetic Resonance Imaging of Bone Marrow and its Results as a Criterion for Administration of Maintenance Therapy After Auto-HSCT in Multiple Myeloma Patients","\u041c\u0430\u0433\u043d\u0438\u0442\u043d\u043e-\u0440\u0435\u0437\u043e\u043d\u0430\u043d\u0441\u043d\u0430\u044f \u0442\u043e\u043c\u043e\u0433\u0440\u0430\u0444\u0438\u044f \u043a\u043e\u0441\u0442\u043d\u043e\u0433\u043e \u043c\u043e\u0437\u0433\u0430 \u0438 \u0435\u0435 \u0440\u0435\u0437\u0443\u043b\u044c\u0442\u0430\u0442\u044b \u043a\u0430\u043a \u043a\u0440\u0438\u0442\u0435\u0440\u0438\u0439 \u043d\u0430\u0437\u043d\u0430\u0447\u0435\u043d\u0438\u044f \u043f\u043e\u0434\u0434\u0435\u0440\u0436\u0438\u0432\u0430\u044e\u0449\u0435\u0439 \u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u043f\u043e\u0441\u043b\u0435 \u0430\u0443\u0442\u043e\u0422\u0413\u0421\u041a \u043f\u0440\u0438 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u0435"],"prefix":"10.21320","volume":"11","author":[{"given":"Maksim Valer\u2019evich","family":"Solov\u2019ev","sequence":"first","affiliation":[{"name":"National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u041d\u041c\u0418\u0426 \u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438\u00bb \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438, \u041d\u043e\u0432\u044b\u0439 \u0417\u044b\u043a\u043e\u0432\u0441\u043a\u0438\u0439 \u043f\u0440-\u0434, \u0434. 4, \u041c\u043e\u0441\u043a\u0432\u0430, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f, 125167"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. P.","family":"Mendeleeva","sequence":"additional","affiliation":[{"name":"National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u041d\u041c\u0418\u0426 \u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438\u00bb \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438, \u041d\u043e\u0432\u044b\u0439 \u0417\u044b\u043a\u043e\u0432\u0441\u043a\u0438\u0439 \u043f\u0440-\u0434, \u0434. 4, \u041c\u043e\u0441\u043a\u0432\u0430, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f, 125167"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. A.","family":"Yatsyk","sequence":"additional","affiliation":[{"name":"National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u041d\u041c\u0418\u0426 \u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438\u00bb \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438, \u041d\u043e\u0432\u044b\u0439 \u0417\u044b\u043a\u043e\u0432\u0441\u043a\u0438\u0439 \u043f\u0440-\u0434, \u0434. 4, \u041c\u043e\u0441\u043a\u0432\u0430, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f, 125167"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. S.","family":"Lutsik","sequence":"additional","affiliation":[{"name":"National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u041d\u041c\u0418\u0426 \u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438\u00bb \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438, \u041d\u043e\u0432\u044b\u0439 \u0417\u044b\u043a\u043e\u0432\u0441\u043a\u0438\u0439 \u043f\u0440-\u0434, \u0434. 4, \u041c\u043e\u0441\u043a\u0432\u0430, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f, 125167"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. V.","family":"Firsova","sequence":"additional","affiliation":[{"name":"National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u041d\u041c\u0418\u0426 \u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438\u00bb \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438, \u041d\u043e\u0432\u044b\u0439 \u0417\u044b\u043a\u043e\u0432\u0441\u043a\u0438\u0439 \u043f\u0440-\u0434, \u0434. 4, \u041c\u043e\u0441\u043a\u0432\u0430, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f, 125167"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. G.","family":"Gemdzhian","sequence":"additional","affiliation":[{"name":"National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u041d\u041c\u0418\u0426 \u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438\u00bb \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438, \u041d\u043e\u0432\u044b\u0439 \u0417\u044b\u043a\u043e\u0432\u0441\u043a\u0438\u0439 \u043f\u0440-\u0434, \u0434. 4, \u041c\u043e\u0441\u043a\u0432\u0430, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f, 125167"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. G.","family":"Savchenko","sequence":"additional","affiliation":[{"name":"National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u041d\u041c\u0418\u0426 \u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438\u00bb \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438, \u041d\u043e\u0432\u044b\u0439 \u0417\u044b\u043a\u043e\u0432\u0441\u043a\u0438\u0439 \u043f\u0440-\u0434, \u0434. 4, \u041c\u043e\u0441\u043a\u0432\u0430, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f, 125167"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8834","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"key":"13837","unstructured":"\u041c\u0435\u043d\u0434\u0435\u043b\u0435\u0435\u0432\u0430 \u041b.\u041f., \u0412\u043e\u0442\u044f\u043a\u043e\u0432\u0430 \u041e.\u041c., \u041f\u043e\u043a\u0440\u043e\u0432\u0441\u043a\u0430\u044f \u041e.\u0421. \u0438 \u0434\u0440. \u041d\u0430\u0446\u0438\u043e\u043d\u0430\u043b\u044c\u043d\u044b\u0435 \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u043f\u043e \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0435 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u044e \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b. \u0413\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f \u0438 \u0442\u0440\u0430\u043d\u0441\u0444\u0443\u0437\u0438\u043e\u043b\u043e\u0433\u0438\u044f. 2016;61(1, \u043f\u0440\u0438\u043b. 2):1\u201324. doi: 10.18821\/0234-5730-2016-61-1(\u041f\u0440\u0438\u043b.2). [Mendeleeva LP, Votyakova OM, Pokrovskaya OS, et al. National clinical guidelines on diagnosis and treatment of multiple myeloma. Gematologiya i transfuziologiya. 2016;61(1, Suppl. 2):1\u201324. doi: 10.18821\/0234-5730-2016-61-1(\u041f\u0440\u0438\u043b.2). (In Russ)]"},{"key":"13838","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"13839","unstructured":"Mendeleeva LP, Solovev MV, Alexeeva A, at al. Multiple Myeloma in Russia (First Results of the Registration Trial). Blood. 2017;130(Suppl 1):5408."},{"key":"13840","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0153-1"},{"key":"13841","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.20"},{"key":"13842","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.381"},{"key":"13843","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8164"},{"key":"13844","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"13845","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0795-0"},{"key":"13846","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.211"},{"key":"13847","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.35"},{"key":"13848","doi-asserted-by":"crossref","unstructured":"Mellqvist UH, Gimsing P, Hjertner O, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013;121(23):4647\u201354. doi: 10.1182\/blood-2012-11-464503.","DOI":"10.1182\/blood-2012-11-464503"},{"key":"13849","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"13850","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"13851","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"13852","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402888"},{"key":"13853","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2260.2260"},{"key":"13854","unstructured":"Solovev MV, Mendeleeva LP, Pokrovskaya OS, et al. The Duration of MRD-Negative Status in Multiple Myeloma (MM) Patients after Auto-HSCT Is a Criterion for Prolonged Remission without Maintenance Therapy. Blood. 2017;130(Suppl 1):3294."},{"key":"13855","doi-asserted-by":"publisher","DOI":"10.1007\/s00256-017-2609-6"},{"key":"13856","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14401"},{"key":"13857","doi-asserted-by":"publisher","DOI":"10.1177\/1971400917699426"},{"key":"13858","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180562"},{"key":"13859","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14849"},{"key":"13860","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14827"},{"key":"13861","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi362"},{"key":"13862","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-015-4195-0"},{"key":"13863","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.5803"},{"key":"13864","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1409207"},{"key":"13865","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0440"},{"key":"13866","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.23"},{"key":"13867","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"13868","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"13869","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.11.010"},{"key":"13870","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1143.1143"},{"key":"13871","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379164"},{"key":"13872","unstructured":"Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial. Blood. 2017;130(Suppl 1):436."},{"key":"13873","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-464503"},{"key":"13874","unstructured":"Phase III Studies Present Additional Evidence for REVLIMID\u00ae (lenalidomide) as Maintenance Therapy in Multiple Myeloma. Available from: http:\/\/ir.celgene.com\/releasedetail.cfm?releaseid=1003026 (accessed 2.05.2018)."},{"key":"13875","doi-asserted-by":"crossref","unstructured":"\u0421\u043e\u043b\u043e\u0432\u044c\u0435\u0432 \u041c.\u0412., \u041c\u0435\u043d\u0434\u0435\u043b\u0435\u0435\u0432\u0430 \u041b.\u041f., \u041f\u043e\u043a\u0440\u043e\u0432\u0441\u043a\u0430\u044f \u041e.\u0421. \u0438 \u0434\u0440. \u041c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u0430\u044f \u043c\u0438\u0435\u043b\u043e\u043c\u0430: \u043f\u043e\u0434\u0434\u0435\u0440\u0436\u0438\u0432\u0430\u044e\u0449\u0430\u044f \u0442\u0435\u0440\u0430\u043f\u0438\u044f \u043f\u043e\u0441\u043b\u0435 \u0442\u0440\u0430\u043d\u0441\u043f\u043b\u0430\u043d\u0442\u0430\u0446\u0438\u0438 \u0430\u0443\u0442\u043e\u043b\u043e\u0433\u0438\u0447\u043d\u044b\u0445 \u0433\u0435\u043c\u043e\u043f\u043e\u044d\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0445 \u0441\u0442\u0432\u043e\u043b\u043e\u0432\u044b\u0445 \u043a\u043b\u0435\u0442\u043e\u043a \u0432 \u0437\u0430\u0432\u0438\u0441\u0438\u043c\u043e\u0441\u0442\u0438 \u043e\u0442 \u043c\u0438\u043d\u0438\u043c\u0430\u043b\u044c\u043d\u043e\u0439 \u043e\u0441\u0442\u0430\u0442\u043e\u0447\u043d\u043e\u0439 \u0431\u043e\u043b\u0435\u0437\u043d\u0438. \u0422\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0430\u0440\u0445\u0438\u0432. 2017;89(7):25\u201331. doi: 10.17116\/terarkh201789725-31.","DOI":"10.17116\/terarkh201789725-31"},{"key":"13876","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh201789725-31"}],"container-title":["Clinical Oncohematology"],"original-title":[],"link":[{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/download\/386\/360","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/download\/386\/360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T11:37:25Z","timestamp":1764502645000},"score":1,"resource":{"primary":{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/view\/386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.21320\/2500-2139-2018-11-4-360-367","relation":{},"ISSN":["2500-2139","1997-6933"],"issn-type":[{"type":"electronic","value":"2500-2139"},{"type":"print","value":"1997-6933"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}